Health insurance startup Alan reaches €5B valuation

Alan raised €100M at a €5B valuation (~$5.83B), up from €4.5B in 2024. The company reported €785M ARR in 2025 (~$915M), +53% year-over-year, says it is operationally profitable in France and has halved losses as a percentage of revenue after net losses of $61M in 2023 and $56M in 2024. Alan is prioritizing international expansion (Belgium, Spain, Canada) and tech/AI investment while targeting $1.16B ARR in 2026 rather than near-term profitability; lead investor Index Ventures was joined by Greenoaks, Kaaf, SH, Belfius and angels including Tobi Lütke and Antoine Griezmann.

Analysis

Alan’s push to operationalize AI inside an insurance stack is a latent margin lever for digital insurers across Europe: better triage, faster claims adjudication, and automated fraud detection can compress loss-adjusted expense ratios by 150–300bps over 12–24 months if models generalize. That margin delta is not merely a profitability play for Alan — it changes pricing dynamics for group buyers and erodes brokers’ recurring commission pools, creating a durable distribution shift toward embedded HR/benefits platforms.

A second-order beneficiary set includes cloud/GPU providers and SM B2B software platforms that can productize benefits administration; conversely, legacy brokers and third-party administrators face a secular headwind to take-rates. Expect measurable effects on RFP outcomes and renewal pricing within the next 2–4 quarters as employers test lower-cost digital alternatives and push for data-driven benchmarking.

Tail risks are regulatory capital treatment and adverse selection if AI-driven underwriting misclassifies risk, which can blow out loss ratios quickly — a 200–400bps miss would erase the current operating leverage story and reprice growth multiples in weeks. Key catalysts to watch are enterprise contract disclosures, incremental ARR cadence, and any public data on claims frequency/severity; these will be the quickest signals to confirm or reverse the market’s current optimism over the next 3–12 months.

Key Decisions for Investors

• Long HPQ (1.5–2% portfolio weight) for 6–12 months: rationale is modest asymmetric upside from increased enterprise refreshes and services attach as embedded benefits providers demand standardized endpoint fleets and support. Enter in two tranches on any <5% pullback; target +20–25% upside, stop-loss -18%.
• Buy MSFT 12-month 10% OTM call spread (size: small, 0.5–1% risk budget): hedge against rising AI infrastructure spend driven by insurtech scale-ups. Max loss = premium; realistic payoff >2x if enterprise AI consumption accelerates, breakeven if cloud growth outpaces consensus by ~200–300bps.
• Short AON (AON) or comparable listed broker (1% portfolio weight) over 6–12 months: thesis is persistent compression of broker take-rates as employers adopt embedded platforms; hedge with a 6–12 month protection (buy 20% OTM put). Aim for 15–30% downside capture if take-rates decline, risk capped if hedged with puts.
• Tactical long NVDA 6-month calls (aggressive, <0.5% portfolio risk): a high-conviction asymmetric bet on continued GPU demand from AI investments across insurtechs. If NVDA rallies >30% on enterprise AI momentum, expect >3x option return; full premium loss is the downside.